This memo provides an update on the House Energy and Commerce Committee’s 21st Century Cures initiative, which has undergone substantial revision since the release of its first legislative draft in January 2015. Read the full memo here.
NAMD sent a letter to the Health Resources and Services Administration (HRSA) and the Centers for Medicare and Medicaid Services (CMS) to share our recent white paper discussing operational challenges in Medicaid’s interaction with the 340B drug discount program. The white paper is available here. Read the full letter here.
This NAMD working paper describes the challenges confronted by Medicaid programs in their interactions with the 340B drug discount program, including inconsistent guidance from federal agencies, the growth of contract pharmacy arrangements, and issues with Medicaid managed care programs. The paper also offers several recommendations to address the identified challenges. Read the full paper here.
The National Association of Medicaid Directors sent a letter to the leaders of the House Energy and Commerce Committee regarding the impact to the Medicaid program from federal legislative efforts to incentivize and expedite high-cost cure-like pharmaceutical treatments and devices. Read the full letter here.
Today the National Association of Medicaid Directors sent the attached letter to the leaders of the Senate Finance and HELP and House Energy & Commerce and Ways & Means committees regarding the current situation with break through prescription drug treatments. The letter addresses the challenges presented by new hepatitis C treatments. It focuses on issues […]
This report outlines the extent of the prescription drug abuse epidemic, its disproportionate impact on Medicaid programs, and provides a series of recommendations to assist states in effectively curbing prescription drug abuse and overdoses. Read the full paper here.
The National Association of Medicaid Directors released a public memo which discusses average acquisition cost (AAC) methodologies for Medicaid prescription drug reimbursement. The memo also provides an update on CMS’s progress finalizing average market price-based Federal Upper Limits (AMP-based FULs) for prescription drugs. Read the full memo here.
NAMD sends letter to CMS Deputy Administrator and Director of Center for Medicaid & CHIP Services Cindy Mann providing additional comments to the Federal Upper Limit (FUL) files and the National Average Drug Acquisition Cost (NADAC) survey. The comments pertain to the Medicaid Outpatient Prescription Drug regulation. Read the full letter here.